any consensus is available about the system to avoid AK. The HAK appeared when the liver is in its final position as demonstrated by our HAK measures (HAF drop-down in all patients). The surgeon or the onment interposition guarantees a maintenance of a good HAF also when the abdominal wall closure is performed.

**O-044** SINGLE CENTER EXPERIENCE OF CONSECUTIVE 500 CASES OF HEPATIC ARTERY ANATOMISISM IN LIVING DONOR LIVER TRANSPLANTATION

Sanghyun Song, Choon Hyuck David Kwon, Jae-Won Joh, Milljae Shin, Jong Man Kim, Sung Joo Kim, Suk-Koo Lee, Hyung Hwan Moon, Sanghoon Lee, Tae-seok Kim, Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

**Background:** Hepatic arterial complication after liver transplantation (LTx) is a major source of morbidity and mortality. Only early diagnosis and treatment will save the patient’s life. We analyzed consecutive more than 500 living donor liver transplantation (LDLT) patients for risk factor and result.

**Method:** From August 2004 to May 2010, total 522 patients including pediatric and adult LDLT were done by our center and donor liver transplants were done by our center and retrospectively reevaluated. Hepatic arterial anastomosis was done under Microscope and by interrupted suture with Prolene #8-0. We routinely checked intrasurgical Doppler at POD#1, #3, #5 or #7. Patients with failed arterial anastomosis included thrombosis and stricture.

**Results:** The overall complication rate related to arterial reconstruction in LDLT was 4.6% (24 cases). 17 patients had an arterial stricture and 7 patients had recurrent thrombus. 2 of them underwent retransplantation because of recurrent thrombosis and hepatic failure. Another 6 patients were treated with interventions. The rest 10 patients were only observed closely under antiplatelet agents because of mild disease severity.

Conclusions: The results of the evaluation of potential living donors at our center and determine the prevalence of macrosteatosis. We aimed to analyze the results of the evaluation of potential living donors at our center and determine the prevalence of macrosteatosis.

**O-045** IMPACT OF PREVALENT STEATOSIS ON OUR LIVING DONOR LIVER TRANSPLANT PROGRAM: ANALYSIS OF 975 LIVING RELATED DONOR LIVERS

Nagla A. Alائم1, Mohamed Alsolahy2, Hatem Khalaf1, Hamad Albah1, Yasser Medhat3, Bassem Hegab4, Hazem Mohamed5, Khalil Alawi6, Hadir Almanna3, Faisal Ababakri3, Yasser Elshelhi3, Moussa Fagush3, Mohamed Neimatallah1, Mohamed Faramawi1, Ayman Abdou1, Mohamed Alsolahy2, Waled Alhamoud2, Health Science, National Liver Institute, Shebaen Al-koam, Egypt; 2Liver Transplantation, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 3Surgery, King Khalid University, Riyadh, Saudi Arabia; 4Pathology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 5Radiology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 6Community Medicine, National Liver Institute, Shebeen Al-koam, Saudi Arabia.

Organ shortage has been the ongoing obstacle to expand liver transplantation world-wide. Living donor liver transplantation (LDLT) was hoped to improve this shortage. We aimed to analyse the results of the evaluation of potential living donors at our center and determine the prevalence of macrosteatosis.

From August 2004 to May 2010, 192 deceased donor transplants and 90 living donors liver transplants (LDLT) were performed. 975 potential living donors were worked up according to a step-wise evaluation protocol. Their age ranged from 16 to 55 years, with 70% in the third and forth decades. They were all first and second degree relatives of the patients.

**Results:** Only 90 (9.2%) were accepted for donation and 885 (90.8%) were rejected. The reasons for rejection are as follows: 80% were excluded at the earlier stages of evaluation: either at initial screening due to high body mass index or due to incompatible blood group, positive hepatitis serology, elevated liver enzymes, miscellaneous systemic diseases, socioeconomic reasons, abnormal anatomy or insufficient volume as determined by CT volumetry. 182 reached the step of liver biopsy. Of these, 44 (24%) were rejected due to abnormal fat content. As regards the remaining 138, 48 were excluded either due to abnormal histopathology (other than steatosis) or the operation was aborted due to the recipients’ condition. Finally 90 underwent donation.

**Conclusion:** There is no doubt that LDLT has helped in alleviating the severe shortage of deceased organs in Saudi Arabia. However suitable living donors are not easy to find especially right lobe donors. Our initial evaluation is effective in eliminating a large number of unsuitable donors. However, steatosis remains a problem encountered at a later stage of the evaluation. The donor evaluation process indeed remains to be a large burden on the resources of our program.

**O-046** MULTICENTER BELGIAN SURVEY ON DONOR MORBIDITY AND MORTALITY IN ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION

Robert J. Troisi1, Dirk Vogelaers1, Jan Lerut2, Olga Ciccarelli2, Francine Roggen1, Jacques Pirrere3, Diether Monbaliu3, Raymond Aerts3, Olivier Detyn3, Arnaud Derover4, Pierre Honoré5, Hans Van Vlierberghe1, Liver Transplant Service, Ghent University Hospital Medical School, Ghent, Belgium; 2Abdominal Transplant Unit, UCL Louvain University Hospital Liege, Liege, Belgium

**Background:** The development of Adult Living Donor Liver Transplantation (ALDLTx) programs in many European LTx centers has decreased due to reported donor morbidity/mortality.

**Methods:** The Belgian Royal Academy of Medicine proposed a national survey to investigate the impact of donor steatosis on ALDLTx. From 09/1999 to 09/2010, 143 ALDLTx were performed in 4 Belgian University Hospitals: UZ-Ghent, UCL-Brussels, KUL-Leuven and ULP-Liege. Median donor age was 53 years (range: 19-59). Majority of donors were children (57%) and spouses (15%).

**Results:** Aborted procedures due to inaccurate preoperative volume assessment were encountered in 7 (5%) donors. 136 donors actually underwent liver resection. 1% donor resection was aborted due to fatty liver histology. Complications occurred in 48/136 (35%), mostly due to UTI (14%), biliary fistula (7%), nerve palsy (5.4%), pulmonary complications (5.4%), early reoperation for bleeding and biliary complications (5.4%) and late reoperation (cirrhotic hemia) (3%). Portal vein thrombosis occurred in 3%. Mean hospital stay was 12±3 days. Hospital readmission was necessary in 3/135 (2.2%) patients. One death occurred in a right lobe donor due to impaired remnant liver regeneration and who expired within a sequential cascade of complications and urgent liver transplantation at post-LTx day 49.

**Conclusions:** Incidence and type of donor complications after ALDLTx in Belgium are comparable to those reported in the ELTR. Donor death is a rare event (0.7%) related to impaired liver remnant regeneration. Inaccurate preoperative assessment also led to procedure abortion in 3%. This emphasizes the need to more reliably predict preoperatively the actual liver volumes and the regeneration capacity of the remnant liver.

**Basic science and immunobiology**

**O-047** INTERLUEKIN-3 PROLONGS ALLOGRAFT SURVIVAL THROUGH REDUCTION OF ANTIBODY MEDIATED CARDIAC REJECTION

Stefan M. Brunner, Gabriela Schiechi, Hans J. Schlitt, Stefan Fichtner-Feigl, Surgery, University Hospital Regensburg, Regensburg, Germany

IL-33 stimulates the generation of cells, cytokine and immunoglobulin production characteristic of a type 2 immune response. In this study, we demonstrate the effect of IL-33 on allograft function during chronic cardiac rejection in mice.

**B6:** C-H2/h12/K0Eg hearts were transplanted into wild type MHC class II-mismatched C57BL/6J mice. IL-33 was administered i.p. daily. Cardiac allografts were harvested, graft infiltrating CD4+ T-cells were isolated and cytokine production was determined by ELISA. Isolated leukocyte populations were examined by flow cytometry and alloantibody levels were determined. Further, immunohistochemical staining of cardiac allografts was performed. Allogeneic transplanted controls showed progressive allograft rejection within 21.5 days after transplantation, whereas allograft survival in IL-33-treated aniridia was extended to more than 50 days. IL-33 allograft survival was significantly increased and significantly increased levels of Th2-cytokines IL-5, IL-13 and antinflammatory IL-10. In addition, IL-33 treatment resulted in homeostatic changes of the lymphoid and myeloid compartment in both the cardiac allografts and periphery. Flow cytometric analyses demonstrated a reduction of grafted CD11b+CD11c+ B-cells following IL-33 therapy. Accordingly, IL-33 treated mice showed reduced alloantibody levels in the serum and less immunoglobulins as determined by immunohistochemical analysis of the grafts. In addition, a significant decrease in graft infiltrating CD11b+Gr+high granulocytes coinciding with a significant increase in suppressive CD11bhigh Gr+intermediate myeloid cells was observed after IL-33 therapy.

IL-33 treatment prolongs allograft survival after cardiac transplantation in mice.